Deutsche Bank
VTGN icon

Deutsche Bank’s VistaGen Therapeutics VTGN Stock Holding History

Deutsche Bank’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,393
Closed -$8.21K – 3827
2023
Q2 		$8.21K Sell
4,393
-4,008
-48% -$14K ﹤0.01% 3667
2023
Q1 		$31.5K Buy
8,401
+5,484
+188% +$28.8K ﹤0.01% 3645
2022
Q4 		$9.01K Sell
2,917
-8,057
-73% -$30.3K ﹤0.01% 3861
2022
Q3 		$50K Buy
10,974
+7,667
+232% +$76K ﹤0.01% 3590
2022
Q2 		$87K Sell
3,307
-443
-12% -$15.6K ﹤0.01% 3579
2022
Q1 		$140K Sell
3,750
-417
-10% -$18.2K ﹤0.01% 3448
2021
Q4 		$244K Buy
4,167
+207
+5% +$13.5K ﹤0.01% 3281
2021
Q3 		$326K Sell
3,960
-2,261
-36% -$196K ﹤0.01% 3302
2021
Q2 		$588K Buy
+6,221
New +$461K ﹤0.01% 3114

Other funds holding VTGN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's VTGN Position: Q3 2023 in Review

Deutsche Bank sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 4,393 shares — an estimated $8.21K sold.

Deutsche Bank first reported a position in VTGN in Q2 2021 and held it in 9 quarters. The position peaked at $588K in Q2 2021. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

  • Deutsche Bank reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Deutsche Bank sold 4,393 VistaGen Therapeutics shares in Q3 2023, an estimated $8.21K.
  • Deutsche Bank first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 9 quarters.
  • Deutsche Bank's VistaGen Therapeutics position peaked at $588K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.